Indefinite Delivery Contract SPE2D221D0134

Award Date 6/8/21
Last Date to Order 6/7/26
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company. The single-award IDC, valued at up to $6,984,109.81, has an ultimate completion date of February 11, 2029. Under this contract, Exelan Pharmaceuticals will provide a variety of generic pharmaceutical products to the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA), a defense agency, to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company. The single-award IDC has a ceiling value of $28,235,184.10 and a period of performance through January 31, 2028. The contract aims to establish a national supply source for Lisinopril tablets in various dosages and quantities to fulfill estimated annual usage for the Department of Defense, Department of...
This Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The single-award, unrestricted IDC has a ceiling value of $4,792,297.44 and a period of performance through December 19, 2025. The contract covers the delivery of a variety of generic pharmaceutical products, including Dofetilide Capsules, to the VA, Department of...
This federal contract IDV, awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Exelan Pharmaceuticals Inc., is a multiple-award Federal Supply Schedule (FSS) contract for pharmaceutical and drug products under FSS-61-IB. The contract has a ceiling value of $3,077,719,680.00 and a period of performance through September 14, 2025. Exelan Pharmaceuticals, a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida, has been awarded various...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company. The IDC has a ceiling value of $7,656,786.70 and a period of performance from June 3, 2025 to June 2, 2026, with four one-year option periods. The contract primarily consists of 6 line items for the delivery of Cyclobenzaprine HCL Tablets in various package sizes, including 30,...
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company. The contract has a ceiling value of $40,480,225.15 and a period of performance from February 12, 2022 to February 11, 2023, with four one-year option periods. The contract was awarded to provide an uninterrupted supply of various strengths and package sizes of...
The federal contract IDV award SPE2D219D0070 was granted to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The IDV is a single-award indefinite delivery contract with a ceiling value of $45,158,494.05 and an ultimate completion date of May 28, 2024. Exelan Pharmaceuticals, a key supplier of generic and branded pharmaceutical products to various federal healthcare agencies, will deliver a diverse range of pharmaceutical items...
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a division of the Department of Veterans Affairs (VA), to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The single-award, unrestricted contract has a ceiling value of $18,098,362.00 and a period of performance from March 2, 2021 to March 1, 2026. The contract is for the delivery of Pregabalin capsules, a generic pharmaceutical product, to the VA,...
This Indefinite Delivery Contract (IDC) was awarded by the VA National Acquisition Center to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The contract has a ceiling value of $10,379,933.80 and a period of performance from October 27, 2022 to October 26, 2025, with four one-year option periods. The contract is for the delivery of Sildenafil Citrate tablets in various strengths and package sizes to support the medication needs of the...
This Indefinite Delivery Contract (IDC) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The single-award contract, valued at a ceiling of $12,802,166.10, is for the delivery of Ramipril capsules in various strengths and package sizes. The period of performance is from March 14, 2022, to March 13, 2023, with four one-year option periods. The...

This Indefinite Delivery Contract (IDC) award to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company, was issued by the Defense Logistics Agency (DLA) with a ceiling value of $5,592,523.40 and a period of performance through June 7, 2026. The contract is for the manufacture and distribution of various pharmaceutical products, primarily generic medications such as ibuprofen, citalopram, oseltamivir phosphate, and alfuzosin HCl, to support federal healthcare programs including the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons, and Indian Health Service.

Exelan Pharmaceuticals holds multiple IDCs across federal agencies, with significant contract values ranging from $5 million to $88 million, focused on repackaging programs that convert bulk pharmaceutical products into patient-ready prescriptions to support cost-effective and efficiently distributed medications to veterans and other federal healthcare beneficiaries. The company also maintains a Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with a potential ceiling value of $3,077,719,680.00, expiring on September 14, 2025. This IDC award was the result of an unrestricted, fully competitive acquisition solicitation posted by the DLA for Alendronate Sodium Tablets, a commercial item procured under FAR Part 12.

Generated 7/22/25, 10:03 AM